Lupin is planning to expand its footprint in Europe by acquiring generics manufacturers for as much as $1 billion. The company is eying those entities that are capable in complex generics like inhalation products and injectables, dermatology products and biosimilar drugs.
Europe is attractive because it has clearer regulations than the US on biosimilars, or copies of biotechnology therapies. Europe contributed 3 percent of Lupin’s sales last year.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
